Abstract:Introduction: Signal transduction cascades drive cellular proliferation, apoptosis, immune, and survival pathways. Proteins have emerged as actionable drug targets because they are often dysregulated in cancer, due to underlying genetic mutations, or dysregulated signaling pathways. Cancer drug development relies on proteomic technologies to identify potential biomarkers, mechanisms-of-action, and to identify protein binding hot spots.Areas covered: Brief summaries of proteomic technologies for drug discovery include mass spectrometry, reverse phase protein arrays, chemoproteomics, and fragment based screening. Protein-protein interface mapping is presented as a promising method for peptide therapeutic development. The topic of biosimilar therapeutics is presented as an opportunity to apply proteomic technologies to this new class of cancer drug.Expert opinion: Proteomic technologies are indispensable for drug discovery. A suite of technologies including mass spectrometry, reverse phase protein arrays, and protein-protein interaction mapping provide complimentary information for drug development. These assays have matured into well controlled, robust technologies. Recent regulatory approval of biosimilar therapeutics provides another opportunity to decipher the molecular nuances of their unique mechanisms of action. The ability to identify previously hidden protein hot spots is expanding the gamut of potential drug targets. Proteomic profiling permits lead compound evaluation beyond the one drug, one target paradigm.

Hunting Molecular Targets for Anticancer Reagents by Chemical Proteomics

Chemical Proteomic Strategies for the Discovery and Development of Anticancer Drugs

Chemical Proteomics to Identify Molecular Targets of Small Compounds

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Proteomics for cancer drug design

Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins

[Chemical Proteomics and Discovery of Drug Targets].

Expression proteomics reveals protein targets and highlights mechanisms of action of small molecule drugs

Target Profiling of an Anticancer Drug Curcumin by an In Situ Chemical Proteomics Approach

Chemoproteomics and Chemical Probes for Target Discovery

Chemical Proteomics: Terra Incognita for Novel Drug Target Profiling

Proteomics approach to illustrate drug action mechanisms.

Functional Metabolomics and Chemoproteomics Approaches Reveal Novel Metabolic Targets for Anticancer Therapy

A Quantitative Chemical Proteomics Approach to Profile the Specific Cellular Targets of Andrographolide, a Promising Anticancer Agent That Suppresses Tumor Metastasis*

Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics

Chemoproteomics: Towards Global Drug Target Profiling

Proteomic profiling predicts drug response to novel targeted anticancer therapeutics

Proteomic methods for drug target discovery

Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs.

Molecular Insights into Cancer Drug Resistance from a Proteomics Perspective

Protein target discovery of drug and its reactive intermediate metabolite by using proteomic strategy